1. Home
  2. MFA vs CTMX Comparison

MFA vs CTMX Comparison

Compare MFA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$9.59

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
CTMX
Founded
1997
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
977.1M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MFA
CTMX
Price
$9.59
$3.77
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$11.05
$12.10
AVG Volume (30 Days)
1.5M
3.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
14.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.02
$7.61
P/E Ratio
$7.75
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$8.78
$1.72
52 Week High
$10.57
$8.21

Technical Indicators

Market Signals
Indicator
MFA
CTMX
Relative Strength Index (RSI) 42.10 34.05
Support Level $9.38 $3.76
Resistance Level $9.79 $3.91
Average True Range (ATR) 0.21 0.22
MACD -0.07 -0.03
Stochastic Oscillator 14.87 9.87

Price Performance

Historical Comparison
MFA
CTMX

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: